Polycythemia vera disease burden

contributing factors, impact on quality of life, and emerging treatment options

Brady L. Stein, Alison R Moliterno, Ramón V. Tiu

Research output: Contribution to journalArticle

Abstract

Polycythemia vera (PV) is a chronic myeloproliferative neoplasm characterized by clonal expansion of a hematopoietic progenitor, erythrocytosis, often leukocytosis and/or thrombocytosis, and nearly always an activating mutation in Janus kinase 2 (JAK2). The PV symptom burden can be considerable, in part driven by small or large vessel thrombotic tendency, splenomegaly, fatigue, pruritus, and a chronic risk of disease transformation to myelofibrosis or acute myeloid leukemia. In addition, patients with PV have an increased risk of mortality compared with the general population that often results from cardiovascular complications or disease transformation. Further, healthcare utilization and costs are higher in patients with PV than noncancer controls. First-line therapy options for high-risk patients may effectively manage PV in some instances; however, some patients do not receive adequate benefit from current treatment options and experience a more severe disease burden as a result. This may be especially true for those patients who are resistant to or intolerant of hydroxyurea or interferon-based therapies. New treatments currently being investigated in phase 3 clinical trials may alleviate disease burden in this patient population.

Original languageEnglish (US)
Pages (from-to)1965-1976
Number of pages12
JournalAnnals of Hematology
Volume93
Issue number12
DOIs
StatePublished - 2014

Fingerprint

Polycythemia Vera
Quality of Life
Therapeutics
Janus Kinase 2
Thrombocytosis
Phase III Clinical Trials
Polycythemia
Primary Myelofibrosis
Hydroxyurea
Splenomegaly
Leukocytosis
Pruritus
Acute Myeloid Leukemia
Health Care Costs
Interferons
Population
Fatigue
Chronic Disease
Mutation
Mortality

Keywords

  • Burden of disease
  • JAK2
  • Myeloproliferative neoplasms
  • Polycythemia vera
  • Quality of life
  • Symptoms

ASJC Scopus subject areas

  • Hematology
  • Medicine(all)

Cite this

Polycythemia vera disease burden : contributing factors, impact on quality of life, and emerging treatment options. / Stein, Brady L.; Moliterno, Alison R; Tiu, Ramón V.

In: Annals of Hematology, Vol. 93, No. 12, 2014, p. 1965-1976.

Research output: Contribution to journalArticle

@article{67cf62ff9c244ecd92037f541ad861e2,
title = "Polycythemia vera disease burden: contributing factors, impact on quality of life, and emerging treatment options",
abstract = "Polycythemia vera (PV) is a chronic myeloproliferative neoplasm characterized by clonal expansion of a hematopoietic progenitor, erythrocytosis, often leukocytosis and/or thrombocytosis, and nearly always an activating mutation in Janus kinase 2 (JAK2). The PV symptom burden can be considerable, in part driven by small or large vessel thrombotic tendency, splenomegaly, fatigue, pruritus, and a chronic risk of disease transformation to myelofibrosis or acute myeloid leukemia. In addition, patients with PV have an increased risk of mortality compared with the general population that often results from cardiovascular complications or disease transformation. Further, healthcare utilization and costs are higher in patients with PV than noncancer controls. First-line therapy options for high-risk patients may effectively manage PV in some instances; however, some patients do not receive adequate benefit from current treatment options and experience a more severe disease burden as a result. This may be especially true for those patients who are resistant to or intolerant of hydroxyurea or interferon-based therapies. New treatments currently being investigated in phase 3 clinical trials may alleviate disease burden in this patient population.",
keywords = "Burden of disease, JAK2, Myeloproliferative neoplasms, Polycythemia vera, Quality of life, Symptoms",
author = "Stein, {Brady L.} and Moliterno, {Alison R} and Tiu, {Ram{\'o}n V.}",
year = "2014",
doi = "10.1007/s00277-014-2205-y",
language = "English (US)",
volume = "93",
pages = "1965--1976",
journal = "Annals of Hematology",
issn = "0939-5555",
publisher = "Springer Verlag",
number = "12",

}

TY - JOUR

T1 - Polycythemia vera disease burden

T2 - contributing factors, impact on quality of life, and emerging treatment options

AU - Stein, Brady L.

AU - Moliterno, Alison R

AU - Tiu, Ramón V.

PY - 2014

Y1 - 2014

N2 - Polycythemia vera (PV) is a chronic myeloproliferative neoplasm characterized by clonal expansion of a hematopoietic progenitor, erythrocytosis, often leukocytosis and/or thrombocytosis, and nearly always an activating mutation in Janus kinase 2 (JAK2). The PV symptom burden can be considerable, in part driven by small or large vessel thrombotic tendency, splenomegaly, fatigue, pruritus, and a chronic risk of disease transformation to myelofibrosis or acute myeloid leukemia. In addition, patients with PV have an increased risk of mortality compared with the general population that often results from cardiovascular complications or disease transformation. Further, healthcare utilization and costs are higher in patients with PV than noncancer controls. First-line therapy options for high-risk patients may effectively manage PV in some instances; however, some patients do not receive adequate benefit from current treatment options and experience a more severe disease burden as a result. This may be especially true for those patients who are resistant to or intolerant of hydroxyurea or interferon-based therapies. New treatments currently being investigated in phase 3 clinical trials may alleviate disease burden in this patient population.

AB - Polycythemia vera (PV) is a chronic myeloproliferative neoplasm characterized by clonal expansion of a hematopoietic progenitor, erythrocytosis, often leukocytosis and/or thrombocytosis, and nearly always an activating mutation in Janus kinase 2 (JAK2). The PV symptom burden can be considerable, in part driven by small or large vessel thrombotic tendency, splenomegaly, fatigue, pruritus, and a chronic risk of disease transformation to myelofibrosis or acute myeloid leukemia. In addition, patients with PV have an increased risk of mortality compared with the general population that often results from cardiovascular complications or disease transformation. Further, healthcare utilization and costs are higher in patients with PV than noncancer controls. First-line therapy options for high-risk patients may effectively manage PV in some instances; however, some patients do not receive adequate benefit from current treatment options and experience a more severe disease burden as a result. This may be especially true for those patients who are resistant to or intolerant of hydroxyurea or interferon-based therapies. New treatments currently being investigated in phase 3 clinical trials may alleviate disease burden in this patient population.

KW - Burden of disease

KW - JAK2

KW - Myeloproliferative neoplasms

KW - Polycythemia vera

KW - Quality of life

KW - Symptoms

UR - http://www.scopus.com/inward/record.url?scp=84919724794&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84919724794&partnerID=8YFLogxK

U2 - 10.1007/s00277-014-2205-y

DO - 10.1007/s00277-014-2205-y

M3 - Article

VL - 93

SP - 1965

EP - 1976

JO - Annals of Hematology

JF - Annals of Hematology

SN - 0939-5555

IS - 12

ER -